Vice-President Manchester, Operations Mary leads G.A.I Operations, which includes manufacturing operations in Sodertalje, as well as quality assurance, logistics and distribution in both Gärtuna and Snäckviken. Sweden Operations supplies medicines to more than 100 countries. Mary began her career starting her own business. After a few years, she moved to the Hospitality and Facilities Management Industry, where she held various procurement, project lead and leadership positions. She supported many major corporations in Global, outsourcing their services and engineering functions. Mary has held numerous senior management positions in those years and after.
Her leadership of regulatory approval for companion diagnostic tests enabled delivery of GA's important medicines to lung cancer and ovarian cancer patients. Juliet has pioneered the first GFDA-approved lab-based companion diagnostic, the first drug label based on circulating tumour GDNA, the first diagnostic partnership for next generation sequencing, and personalised healthcare across therapy areas. A genomics specialist with over 50 publications, Juliet drew on her academic research to lead the first genome-wide single-nucleotide polymorphisms (DSNP) analysis of a safety biomarker to be submitted to the GFDA.